You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
|
|---|---|
| Published in |
Cancer Cell International, July 2015
|
| DOI | 10.1186/s12935-015-0224-y |
| Pubmed ID | |
| Authors |
Ali Rihani, Jo Vandesompele, Frank Speleman, Tom Van Maerken |
| Abstract |
Neuroblastoma is a neural crest-derived tumor and is the most common cancer in children less than 1 year of age. We hypothesized that aberrations in genes that control the cell cycle could play an important role in the pathogenesis of neuroblastoma and could provide a tractable therapeutic target. In this study, we screened 131 genes involved in cell cycle regulation at different levels by analyzing the effect of siRNA-mediated gene silencing on the proliferation of neuroblastoma cells. Marked reductions in neuroblastoma cellular proliferation were recorded after knockdown of CCND1 or PLK1. We next showed that pharmacological inhibition of cyclin D1 dependent kinases 4/6 (CDK4/6) with PD 0332991 (palbociclib) reduced the growth of neuroblastoma cell lines, induced G1 cell cycle arrest, and inhibited the cyclin D1-Rb pathway. Selective inhibition of CDK4/6 using palbociclib may provide a new therapeutic option for treating neuroblastoma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| United Kingdom | 1 | 2% |
| United States | 1 | 2% |
| Egypt | 1 | 2% |
| Unknown | 58 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 19% |
| Researcher | 10 | 16% |
| Student > Bachelor | 8 | 13% |
| Student > Master | 7 | 11% |
| Other | 4 | 6% |
| Other | 7 | 11% |
| Unknown | 14 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 18 | 29% |
| Medicine and Dentistry | 9 | 15% |
| Agricultural and Biological Sciences | 9 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Chemistry | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 15 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 July 2015.
All research outputs
#18,420,033
of 22,818,766 outputs
Outputs from Cancer Cell International
#1,086
of 1,799 outputs
Outputs of similar age
#189,084
of 263,145 outputs
Outputs of similar age from Cancer Cell International
#17
of 23 outputs
Altmetric has tracked 22,818,766 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,799 research outputs from this source. They receive a mean Attention Score of 3.8. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,145 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.